182 related articles for article (PubMed ID: 18272363)
1. Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.
Costanzo MJ; Yabut SC; Zhang HC; White KB; de Garavilla L; Wang Y; Minor LK; Tounge BA; Barnakov AN; Lewandowski F; Milligan C; Spurlino JC; Abraham WM; Boswell-Smith V; Page CP; Maryanoff BE
Bioorg Med Chem Lett; 2008 Mar; 18(6):2114-21. PubMed ID: 18272363
[TBL] [Abstract][Full Text] [Related]
2. Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone.
Costanzo MJ; Yabut SC; Almond HR; Andrade-Gordon P; Corcoran TW; De Garavilla L; Kauffman JA; Abraham WM; Recacha R; Chattopadhyay D; Maryanoff BE
J Med Chem; 2003 Aug; 46(18):3865-76. PubMed ID: 12930148
[TBL] [Abstract][Full Text] [Related]
3. Upgrading a natural product: inhibition of human beta-tryptase by cyclotheonamide analogues.
Schaschke N; Sommerhoff CP
ChemMedChem; 2010 Mar; 5(3):367-70. PubMed ID: 20077463
[No Abstract] [Full Text] [Related]
4. Synthesis and evaluation of 4-substituted benzylamine derivatives as beta-tryptase inhibitors.
Miyazaki Y; Kato Y; Manabe T; Shimada H; Mizuno M; Egusa T; Ohkouchi M; Shiromizu I; Matsusue T; Yamamoto I
Bioorg Med Chem Lett; 2006 Jun; 16(11):2986-90. PubMed ID: 16540315
[TBL] [Abstract][Full Text] [Related]
5. Formation of active monomers from tetrameric human beta-tryptase.
Fajardo I; Pejler G
Biochem J; 2003 Feb; 369(Pt 3):603-10. PubMed ID: 12387726
[TBL] [Abstract][Full Text] [Related]
6. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore.
Pereira PJ; Bergner A; Macedo-Ribeiro S; Huber R; Matschiner G; Fritz H; Sommerhoff CP; Bode W
Nature; 1998 Mar; 392(6673):306-11. PubMed ID: 9521329
[TBL] [Abstract][Full Text] [Related]
7. Structure-based library design and the discovery of a potent and selective mast cell β-tryptase inhibitor as an oral therapeutic agent.
Liang G; Aldous S; Merriman G; Levell J; Pribish J; Cairns J; Chen X; Maignan S; Mathieu M; Tsay J; Sides K; Rebello S; Whitely B; Morize I; Pauls HW
Bioorg Med Chem Lett; 2012 Jan; 22(2):1049-54. PubMed ID: 22192588
[TBL] [Abstract][Full Text] [Related]
8. Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation.
Hopkins C; Neuenschwander K; Scotese A; Jackson S; Nieduzak T; Pauls H; Liang G; Sides K; Cramer D; Cairns J; Maignan S; Mathieu M
Bioorg Med Chem Lett; 2004 Oct; 14(19):4819-23. PubMed ID: 15341931
[TBL] [Abstract][Full Text] [Related]
9. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
Sutton JC; Bolton SA; Davis ME; Hartl KS; Jacobson B; Mathur A; Ogletree ML; Slusarchyk WA; Zahler R; Seiler SM; Bisacchi GS
Bioorg Med Chem Lett; 2004 May; 14(9):2233-9. PubMed ID: 15081015
[TBL] [Abstract][Full Text] [Related]
10. Secondary structure peptide mimetics: design, synthesis, and evaluation of beta-strand mimetic thrombin inhibitors.
Boatman PD; Ogbu CO; Eguchi M; Kim HO; Nakanishi H; Cao B; Shea JP; Kahn M
J Med Chem; 1999 Apr; 42(8):1367-75. PubMed ID: 10212122
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.
Bisacchi GS; Slusarchyk WA; Bolton SA; Hartl KS; Jacobs G; Mathur A; Meng W; Ogletree ML; Pi Z; Sutton JC; Treuner U; Zahler R; Zhao G; Seiler SM
Bioorg Med Chem Lett; 2004 May; 14(9):2227-31. PubMed ID: 15081014
[TBL] [Abstract][Full Text] [Related]
12. The arginine mimicking β-amino acid β³hPhe(3-H₂N-CH₂) as S1 ligand in cyclotheonamide-based β-tryptase inhibitors.
Janke D; Sommerhoff CP; Schaschke N
Bioorg Med Chem; 2011 Dec; 19(23):7236-43. PubMed ID: 22047802
[TBL] [Abstract][Full Text] [Related]
13. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.
Choi-Sledeski YM; Kearney R; Poli G; Pauls H; Gardner C; Gong Y; Becker M; Davis R; Spada A; Liang G; Chu V; Brown K; Collussi D; Leadley R; Rebello S; Moxey P; Morgan S; Bentley R; Kasiewski C; Maignan S; Guilloteau JP; Mikol V
J Med Chem; 2003 Feb; 46(5):681-4. PubMed ID: 12593648
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological activity of piperidine diamine derivatives as factor Xa inhibitor.
Mochizuki A; Nakamoto Y; Naito H; Uoto K; Ohta T
Bioorg Med Chem Lett; 2008 Jan; 18(2):782-7. PubMed ID: 18039572
[TBL] [Abstract][Full Text] [Related]
15. Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep.
Elrod KC; Moore WR; Abraham WM; Tanaka RD
Am J Respir Crit Care Med; 1997 Aug; 156(2 Pt 1):375-81. PubMed ID: 9279212
[TBL] [Abstract][Full Text] [Related]
16. X-ray structures of free and leupeptin-complexed human alphaI-tryptase mutants: indication for an alpha-->beta-tryptase transition.
Rohr KB; Selwood T; Marquardt U; Huber R; Schechter NM; Bode W; Than ME
J Mol Biol; 2006 Mar; 357(1):195-209. PubMed ID: 16414069
[TBL] [Abstract][Full Text] [Related]
17. Mast cell tryptase beta as a target in allergic inflammation: an evolving story.
Sommerhoff CP; Schaschke N
Curr Pharm Des; 2007; 13(3):313-32. PubMed ID: 17313363
[TBL] [Abstract][Full Text] [Related]
18. Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.
Sperandio D; Tai VW; Lohman J; Hirschbein B; Mendonca R; Lee CS; Spencer JR; Janc J; Nguyen M; Beltman J; Sprengeler P; Scheerens H; Lin T; Liu L; Gadre A; Kellogg A; Green MJ; McGrath ME
Bioorg Med Chem Lett; 2006 Aug; 16(15):4085-9. PubMed ID: 16725321
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy]-pen tane (AMG-126737).
Wright CD; Havill AM; Middleton SC; Kashem MA; Dripps DJ; Abraham WM; Thomson DS; Burgess LE
Biochem Pharmacol; 1999 Dec; 58(12):1989-96. PubMed ID: 10591155
[TBL] [Abstract][Full Text] [Related]
20. Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity.
Rice KD; Wang VR; Gangloff AR; Kuo EY; Dener JM; Newcomb WS; Young WB; Putnam D; Cregar L; Wong M; Simpson PJ
Bioorg Med Chem Lett; 2000 Oct; 10(20):2361-6. PubMed ID: 11055356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
